Clinical Trials Logo

Clinical Trial Summary

This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.


Clinical Trial Description

The Optum EHR database was current up to 30-Jun-2020. Identification period: From 01-Apr-2007 to 30-Jun-2019 Study period: From 01-Jan-2007 to 30-Jun-2020 Index date: First evidence of resistance to or intolerance of HU treatment in patients with PV according to modified European Leukemia Net (ELN) criteria and defined as: 1. HCT ≥ 45% with phlebotomy (last phlebotomy within last 3 months) Or 2. Platelet count > 400 x 109/L and presence of palpable splenomegaly (palpable spleen up to 3 months after platelet count) Pre-index period: Patients had a minimum of 3 months pre-index data available. Pre-index data availability was determined using the reported 'first month active' field. Post-index period: There was no minimum post-index period required. Each patient had a 'first month active' and 'last month active' reported within the database. As the 'last month active' was based on any activity in the database, including encounters such as letters and emails which occurred several months after the 'death_date' of the patient, using the 'last month active' can overestimate the follow-up for a given patient. For this reason, the end of follow-up for each patient was defined as the date of the last activity within the diagnosis, observations, prescriptions, laboratories, procedures tables or discharge date from the last visit within the visit table (whichever of these activities occurs latest). This underestimated the follow-up for some patients where they were not actively using healthcare resources. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05421104
Study type Observational
Source Novartis
Contact
Status Completed
Phase
Start date November 27, 2020
Completion date June 29, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02577926 - The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Phase 2
Recruiting NCT06002490 - A Study to Evaluate P1101 in Japanese PV Patients Phase 3
Completed NCT01816256 - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms N/A
Recruiting NCT04655092 - Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients Phase 3
Completed NCT04243122 - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Phase 2
Completed NCT04182100 - Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply Phase 2
Available NCT04745637 - Managed Access Programs for INC424, Ruxolitinib